Inhaled Solid Lipid Microparticles to target alveolar macrophages for tuberculosis

International Journal of Pharmaceutics

Volumn 462, Issue 1-2, 2014, Pages 74-82

  Maretti, Eleonora ^a   Rossi, Tiziana ^a   Bondi, Moreno ^a   Croce, Maria Antonietta ^a   Hanuskova, Miriam ^a   Leo, Eliana ^a   Sacchetti, Francesca ^a   Iannuccelli, Valentina ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Inhaled therapy; Rifampicin; Solid Lipid Microparticles; Tuberculosis

Indexed keywords

RIFAMPICIN; SOLID LIPID NANOPARTICLE; STEARIC ACID; TAUROCHOLIC ACID;

AERODYNAMIC DIAMETER; ANIMAL TISSUE; ANTIMICROBIAL ACTIVITY; ARTICLE; BACILLUS SUBTILIS; BACTERIAL STRAIN; CONFOCAL LASER MICROSCOPY; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; CYTOFLUOROMETRY; CYTOSOL; DRUG RETENTION; DRUG SOLUBILITY; DRUG UPTAKE; DYNAMICS; EMULSION; ENDOCYTOSIS; FEMALE; IN VITRO STUDY; INTERNALIZATION; LUNG ALVEOLUS EPITHELIUM; LUNG ALVEOLUS MACROPHAGE; MOUSE; MTT ASSAY; MURINAE; NONHUMAN; PARTICLE SIZE; PREFORMULATION; PRIORITY JOURNAL; SURFACE CHARGE; TARGET CELL; TUBERCULOSIS;

INHALED THERAPY; RIFAMPICIN; SOLID LIPID MICROPARTICLES; TUBERCULOSIS;

ADMINISTRATION, INHALATION; ANIMALS; ANTITUBERCULAR AGENTS; BACILLUS SUBTILIS; CELL LINE; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRY POWDER INHALERS; FLOW CYTOMETRY; LIPIDS; MACROPHAGES, ALVEOLAR; MICE; MICROSCOPY, CONFOCAL; MICROSPHERES; PARTICLE SIZE; RIFAMPIN; STEARIC ACIDS; TAUROCHOLIC ACID; TUBERCULOSIS;

EID: 84892169113     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2013.12.034     Document Type: Article

References (58)

1. Q. Ain, S. Sharma, G.K. Khuller, and K. Grag Alginate-based oral drug delivery system for tuberculosis: pharmacokinetics and therapeutic effects J. Antimicrob. Chemother. 51 2003 931 938 (Pubitemid 36503426)
2. P. Bemer-Melchior, A. Bryskier, and H.B. Drugeon Comparison of the in vitro activities of rifapentine and rifampicin against Mycobacterium tuberculosis complex J. Antimicrob. Chemother. 46 2000 571 575
3. P. Blasi, A. Schoubben, S. Giovagnoli, C. Rossi, and M. Ricci Fighting tuberculosis: old drugs, new formulation Expert Opin. Drug. Deliv. 6 2009 977 993
4. B. Blomberg, S. Spinaci, and B. Fourie The rationale for recommending fixed-dose combination tablets for treatment of tuberculosis Bull. World Health Org. 79 2001 61 68 (Pubitemid 32154097)
5. N. Brandhonneur, F. Chevanne, V. Vié, B. Frisch, R. Primault, M.F. Le Potier, and P. Le Corre Specific and non-specific phagocytosis of ligand-grafted PLGA microspheres by macrophages Eur. J. Pharm. Sci. 36 2009 474 485
6. S.P. Chaturvedi, and V. Kumar Production techniques of lipid nanoparticles: a review Res. J. Pharm. Biol. Chem. Sci. 3 2012 525 541
7. S. Chono, T. Tanino, T. Seki, and K. Morimoto Uptake characteristics of liposomes by rat alveolar macrophages: influence of particle size and surface mannose modification J. Pharm. Pharmacol. 59 2007 75 80 (Pubitemid 46133045)
8. J. Chuan, Y. Li, L. Yang, X. Sun, Q. Zhang, T. Gong, and Z. Zhang Enhanced rifampicin delivery to alveolar macrophages by solid lipid nanoparticles J. Nanopart. Res. 15 2013 1634 1642
9. A. Dey, and D. Chatterji Tracing the variation in physiological response to rifampicin across the microbial spectrum J. Bacteriol. Virol. 42 2012 87 100
10. M. Dutt, and G.K. Khuller Chemotherapy of Mycobacterium tuberculosis infections in mice with a combination of isoniazid and rifampicin entrapped in poly-(dl-lactide-co-glycolide) microparticles J. Antimicrob. Chemother. 47 2001 829 835 (Pubitemid 32519831)
11. D.A. Edwards Delivery of biological agents by aerosols AIChE J. 48 2002 1 6
12. D. Edwards Applications of capsule dosing techniques for use in dry powder inhalers Ther. Deliv. 1 2010 195 201
13. R. Falk, T.W. Randolph, J.D. Meyer, R.M. Kelly, and M.C. Manning Controlled release of ionic compounds from poly (l-lactide) microspheres produced by precipitation with a compressed antisolvent J. Control. Release 44 1997 77 85 (Pubitemid 27051336)
14. E.P. Geiduschek, and J. Sklar Role of host RNA polymerase in phage development: continual requirement for a host RNA polymerase component in a bacteriophage development Nature 221 1969 833 836
15. H. Hamishehkar, Y. Rahimpour, and Y. Javadzadeh The role of carrier in dry powder inhaler A.D. Sezer, Recent Advances in Novel Drug Carrier System 2012 InTech Open Access Publisher 39 66
16. K. Hirota, and H. Terada Endocytosis of particle formulations by macrophages and its application to clinical treatment B. Ceresa, Molecular Regulation of Endocytosis 2012 InTech Open Access Publisher 413 428
17. V. Iannuccelli, G. Coppi, S. Sergi, and R. Cameroni Preparation and in vitro characterization of lipospheres as a carrier for the cosmetic application of glycolic acid J. Appl. Cosmet. 19 2001 113 119
18. V. Iannuccelli, N. Sala, R. Tursilli, G. Coppi, and S. Scalia Influence of liposphere preparation on butyl-methoxydibenzoylmethane photostability Eur. J. Pharm. Biopharm. 63 2006 140 145 (Pubitemid 43776210)
19. V. Iannuccelli, G. Coppi, M. Romagnoli, S. Sergi, and E. Leo In vivo detection of lipid based nano- and microparticles in the outermost human stratum corneum by EDX analysis Int. J. Pharm. 447 2013 204 2012
20. O.R. Justo, and A.M. Moraes Incorporation of antibiotics in liposomes designed for tuberculosis therapy by inhalation Drug Deliv. 10 2003 201 207 (Pubitemid 36993372)
21. F. Kaneko, M. Kobayashi, Y. Kitagawa, and Y. Matsuura Structure of stearic acid E form Acta Crystallogr. C46 1990 1490 1492
22. S.K. Katiyar, S. Bihari, and S. Prakash Low-dose inhaled versus standard dose oral form of anti-tubercular drugs: concentrations in bronchial epithelial lining fluid, alveolar macrophage and serum J. Postgrad. Med. 54 2008 245 246 (Pubitemid 352009182)
23. C. Kelly, C. Jefferies, and S.A. Cryan Targeted liposomal drug delivery to monocytes and macrophages J. Drug Deliv. 2011 2010 1 11
24. B. Kong, J.H. Seog, L.M. Graham, and S.B. Lee Experimental considerations on the cytotoxicity of nanoparticles Nanomedicine 6 2011 929 941
25. C. Lawlor, M.P. O'Sullivan, N. Sivadas, S. O'Leary, P.J. Gallagher, J. Keane, and S.A. Cryan The application of high-content analysis in the study of targeted particulate delivery systems for intracellular drug delivery to alveolar macrophages Mol. Pharm. 8 2011 1100 1112
26. C. Lawlor, C. Kelly, S. O'Leary, M.P. O'Sallivan, P.J. Gallagher, J. Keane, and S.A. Cryan Cellular targeting and trafficking of drug delivery systems for the prevention and treatment of MTb Tuberculosis 91 2011 93 97
27. W. Lee, B.C. Vander Ven, R.J. Fahey, and D.G. Russell Intracellular Mycobacterium tuberculosis exploits host-derived fatty acids to limit metabolic stress J. Biol. Chem. 288 2013 6788 6800
28. M.L. Manca, C. Sinico, A.M. Maccioni, O. Diez, A.M. Fadda, and M. Manconi Composition influence on pulmonary delivery of rifampicin liposomes Pharmaceutics 4 2012 590 606
29. T.T. Mariappan, N. Sharda, and S. Singh Atypical log D profile of rifampicin Indian J. Pharm. Sci. 69 2007 197 201 (Pubitemid 47026098)
30. T. Mosmann Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays J. Immunol. Methods 65 1983 55 63 (Pubitemid 14203433)
31. P. Muttil, J. Kaur, K. Kumar, A.B. Yadav, R. Sharma, and A. Misra Inhalable microparticles containing large payload of anti-tuberculosis drugs Eur. J. Pharm. Sci. 32 2007 140 150 (Pubitemid 47285721)
32. M. Nassimi, C. Schleh, H.D. Lauenstein, R. Hussein, H.G. Hoymann, W. Koch, G. Pohlmann, N. Krug, K. Sewald, S. Rittinghausen, A. Braun, and C. Müller-Goymann A toxicological evaluation of inhaled solid lipid nanoparticles used as a potential drug delivery system for the lung Eur. J. Pharm. Biopharm. 75 2010 107 116
33. R. Panchagnula, and V. Bhardwaj Effect of amorphous content on dissolution characteristics of rifampicin Drug Dev. Ind. Pharm. 34 2008 642 649 (Pubitemid 351878683)
34. R. Pandey, A. Sharma, A. Zahoor, S. Sharma, G.K. Khuller, and B. Prasad Poly (dl-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis J. Antimicrob. Chemother. 52 2003 981 986 (Pubitemid 38008419)
35. R. Pandey, S. Sharma, and G.K. Khuller Nebulization of liposome encapsulated antitubercular drugs in guinea pigs Int. J. Antimicrob. Agents 24 2004 93 94 (Pubitemid 38844571)
36. R. Pandey, S. Sharma, and G.K. Khuller Oral solid lipid nanoparticle-based antitubercular chemotherapy Tuberculosis 85 2005 415 420 (Pubitemid 41617396)
37. R. Pandey, and G.K. Khuller Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis Tuberculosis 85 2005 227 234 (Pubitemid 40805619)
38. G. Pilcer, and K. Amighi Formulation strategy and use of excipients in pulmonary drug delivery Int. J. Pharm. 392 2010 1 19
39. W. Rojanarat, T. Nakpheng, E. Thawithong, N. Yanyum, and T. Srichana Inhaled pyrazinamide proliposome for targeting alveolar macrophages Drug Deliv. 19 2012 334 345
40. N. Schöler, H. Hahn, R.H. Müller, and O. Liesenfeld Effect of lipid matrix and size of solid lipid nanoparticles (SLN) on the viability and cytokine production of macrophages Int. J. Pharm. 231 2002 167 176 (Pubitemid 34033676)
41. R. Sharma, D. Saxena, A.K. Dwivedi, and A. Misra Inhalable microparticles containing drug combinations to target alveolar macrophages for treatment of pulmonary tuberculosis Pharm. Res. 18 2001 1405 1410 (Pubitemid 32977245)
42. R. Sharma, P. Muttil, A.B. Yadav, S.K. Rath, V.K. Bajpai, U. Mani, and A. Misra Uptake of inhalable microparticles affects defence responses of macrophages infected with Mycobacterium tuberculosis H37Ra J. Antimicrob. Chemother. 59 2007 499 506 (Pubitemid 47073457)
43. V. Sihorkar, and S.P. Vyas Potential of polysaccharide anchored liposomes in drug delivery, targeting and immunization J. Pharm. Pharm. Sci. 4 2001 138 158 (Pubitemid 34305606)
44. M. Singh, P. Sasi, G. Rai, V.H. Gupta, D. Amarapurkar, and P.P. Wangikar Studies on toxicity of antitubercular drugs namely isoniazid, rifampicin, and pyrazinamide in an in vitro model of HepG2 cell line Med. Chem. Res. 20 2011 1611 1615
45. Y.J. Son, J.P. Mitchell, and J.T. McConville In vitro performance testing for pulmonary drug delivery H.D. Smith, A.J. Hickey, Controlled Pulmonary Drug Delivery 2011 Springer New York 383 416
46. M. Takenaga, Y. Ohta, Y. Tokura, A. Hamaguchi, and R. Igarashi Lipid microsphere formulation containing rifampicin targets alveolar macrophages Drug Deliv. 15 2008 169 175 (Pubitemid 351465714)
47. A.C.T. Teixeira, A.M.P.S. Gonçalves da Silva, and A.C. Fernandes Phase behaviour of stearic acid-stearonitrile mixtures. A thermodynamic study in bulk and at the air-water interface Chem. Phys. Lipids 144 2006 160 171 (Pubitemid 44737474)
48. A. Tostmann, M.J. Boeree, W.H. Peters, H.M. Roelofs, R.E. Aarnoutse, A.J. van der Ven, and P.N. Dekhuijzen Isoniazid and its toxic metabolite hydrazine induce in vitro pyrazinamide toxicity Int. J. Antimicrob. Agents 31 2008 577 580
49. M.V. Vadakkan, K. Annapoorna, K.C. Sivakumar, S. Mundayoor, and G.S. Kumar Dry powder cationic lipopolymeric nanomicelle inhalation for targeted delivery of antitubercular drug to alveolar macrophage Int. J. Nanomed. 8 2013 2871 2885
50. S.P. Vyas, M.E. Kannan, S. Jain, V. Mishra, and P. Singh Design of liposomal aerosols for improved delivery of rifampicin to alveolar macrophages Int. J. Pharm. 269 2004 37 49 (Pubitemid 38035210)
51. W.A. Wallace, M. Gillooly, and D. Lamb Intra-alveolar macrophage number in current smokers and non-smokers: morphometric study of tissue section Thorax 47 1992 437 440
52. S. Weber, A. Zimmer, and J. Pardeike Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for pulmonary application: a review of the state of the art Eur. J. Pharm. Biopharm. 2013 10.1016/j.ejpb.2013.08.013
53. W.D. Winters, A.L. Tuan, and D.L. Morton Differential effects of rifampicin on cultured human tumor cells Cancer Res. 34 1974 3173 3179
54. World Health Organization Global Tuberculosis Report 2012 (WHO/HTM/TB/2012.6) 2012 The Organization Geneva, Switzerland
55. A. Zahoor, S. Sharma, and G.K. Khuller Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis Int. J. Antimicrob. Agents 26 2005 298 303 (Pubitemid 41338657)
56. M. Zaru, C. Sinico, A. De Logu, C. Caddeo, F. Lai, M.L. Manca, and A.M. Fadda Rifampicin-loaded liposomes for the passive targeting to alveolar macrophages: in vitro and in vivo evaluation J. Liposome Res. 19 2009 68 76
57. L. Zhang, D. Pornpattananangkul, C.M.J. Hu, and C.-M. Huang Development of nanoparticles for antimicrobial drug delivery Curr. Med. Chem. 17 2010 585 594
58. H.M. Ziglam, D.R. Baldwin, I. Daniels, J.M. Andrew, and R.G. Finch Rifampicin concentrations in bronchial mucosa, epithelial lining fluid, alveolar macrophages and serum following a single 600 mg oral dose in patients undergoing fibre-optic bronchoscopy J. Antimicrob. Chemother. 50 2002 1011 1015 (Pubitemid 36032825)